J Korean Med Sci.  2011 Jan;26(1):85-91. 10.3346/jkms.2011.26.1.85.

Initial Biopsy Outcome Prediction in Korean Patients-Comparison of a Noble Web-based Korean Prostate Cancer Risk Calculator versus Prostate-specific Antigen Testing

• Park JY
• Yoon S
• Park MS
• Cho DY
• Park HS
• Moon DG
• Yoon DK

• KMID: 1777981
• DOI: http://doi.org/10.3346/jkms.2011.26.1.85

Abstract

We developed and validated a novel Korean prostate cancer risk calculator (KPCRC) for predicting the probability of a positive initial prostate biopsy in a Korean population. Data were collected from 602 Koreans who underwent initial prostate biopsies due to an increased level of prostate-specific antigen (PSA), a palpable nodule upon digital rectal examination (DRE), or a hypoechoic lesion upon transrectal ultrasound (TRUS). The clinical and laboratory variables were analyzed by simple and multiple logistic regression analysis. The area under the receiver operating characteristic curve (AUC) was computed to compare its performance to PSA testing alone. Prostate cancer was detected in 172 (28.6%) men. Independent predictors included age, DRE findings, PSA level, and prostate transitional zone volume. We developed the KPCRC using these variables. The AUC for the selected model was 0.91, and that of PSA testing alone was 0.83 (P < 0.001). The AUC for the selected model with an additional dataset was 0.79, and that of PSA testing alone was 0.73 (P = 0.004). The calculator is available on the website: http://dna.korea.ac.kr/PC-RISC/. The KPCRC improved the performance of PSA testing alone in predicting the risk of prostate cancer in a Korean population. This calculator would be a practical tool for physicians and patients.

Keyword

Prostate Neoplasms; Biopsy; Forecasting; Asian Continental Ancestry Group

MeSH Terms

Aged
Area Under Curve
Biopsy, Needle
*Digital Rectal Examination
Humans
Internet
Male
Middle Aged
Predictive Value of Tests
Prostate/pathology
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/*diagnosis/pathology/ultrasonography
ROC Curve
Republic of Korea
Risk

Figure

• 

  Fig. 1 Receiver operating characteristics curve for our model and prostate specific antigen (A) in 602 patients who underwent initial prostate biopsies (P < 0.001), (B) in 324 patients from additional dataset for the external validation (P = 0.004).

Reference

1. Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette LUC, Scardino PT, Cagiannos I, Heinzer H, Tanguay S, Aprikian AG, Huland H, Graefen M. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol. 2005. 173:1930–1934.

2. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, Park EC, Lee JS. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci. 2010. 25:1113–1121.

3. Jung KW, Won YJ, Park S, Kong HJ, Sung J, Shin HR, Park EC, Lee JS. Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci. 2009. 24:995–1003.

4. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991. 145:907–923.

5. el-Galley RE, Petros JA, Sanders WH, Keane TE, Galloway NT, Cooner WH, Graham SD Jr. Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urology. 1995. 46:200–204.

6. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995. 154:407–413.

7. Kalish J, Cooner WH, Graham SD Jr. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology. 1994. 43:601–606.

8. Gohji K, Nomi M, Egawa S, Morisue K, Takenaka A, Okamoto M, Ohori M, Fujii A. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations. Cancer. 1997. 79:1969–1976.

9. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-apecific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998. 279:1542–1547.

10. Kawamura K, Suzuki H, Kamiya N, Imamoto T, Yano M, Miura J, Shimbo M, Suzuki N, Nakatsu H, Ichikawa T. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL. Int J Urol. 2008. 15:598–603.

11. Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M, Beer TM, Klein T. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL. Cancer. 2003. 98:1417–1422.

12. Yanke BV, Carver BS, Bianco FJ Jr, Simoneaux WJ, Venable DD, Powell IJ, Eastham JA. African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram. BJU Int. 2006. 98:783–787.

13. Nam RK, Toi A, Klotz LH, Trachtenberg J, Jewett MA, Appu S, Loblaw DA, Sugar L, Narod SA, Kattan MW. Assessing individual risk for prostate cancer. J Clin Oncol. 2007. 25:3582–3588.

14. Suzuki H, Komiya A, Kamiya N, Imamoto T, Kawamura K, Miura J, Suzuki N, Nakatsu H, Hata A, Ichikawa T. Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients. Urology. 2006. 67:131–136.

15. Cho TW, Kim SH, Park D. Development of statistical model for predicting prostate cancer in patients requiring prostate biopsy. Korean J Urol. 2004. 45:1014–1020.

16. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983. 148:839–843.

17. Carlson GD, Calvanese CB, Partin AW. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology. 1998. 52:455–461.

18. Chun FK, Briganti A, Graefen M, Montorsi F, Porter C, Scattoni V, Gallina A, Walz J, Haese A, Steuber T, Erbersdobler A, Schlomm T, Ahyai SA, Currlin E, Valiquette L, Heinzer H, Rigatti P, Huland H, Karakiewicz PI. Development and external validation of an extended 10-core biopsy nomogram. Eur Urol. 2007. 52:436–445.

19. Kawakami S, Numao N, Okubo Y, Koga F, Yamamoto S, Saito K, Fujii Y, Yonese J, Masuda H, Kihara K, Fukui I. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy. Eur Urol. 2008. 54:601–611.

20. Zlotta AR, Djavan B, Marberger M, Schulman CC. Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol. 1997. 157:1315–1321.

21. Kang SH, Bae JH, Park HS, Yoon DK, Moon DG, Kim JJ, Cheon J. Prostate-specific antigen adjusted for the transition zone volume as a second screening test: a prospective study of 248 cases. Int J Urol. 2006. 13:910–914.

22. Song C, Ro JY, Lee MS, Hong SJ, Chung BH, Choi HY, Lee SE, Lee E, Kim CS, Ahn H. Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy. Urology. 2006. 68:820–824.